Immuno-oncology--Tn-specific monoclonal IgM antibody binds and kills human tumor cells


Project ID: D2015-13


IP Status: PCT application filed


Invention Description: Newly developed IgM antibody has been shown to bind to known cancer cells in flow cytometry and demonstrates complement mediated killing of human tumor cells, both in vivo and in vitro. Unique therapeutic approach to targeting carbohydrates and malignant cells: Monoclonal IgM antibody binds TACA Thomsen-nouveau (Tn) which is present on the surface of 80-90% of all cancers, including breast, colon, bladder, ovarian, stomach, and prostate.



Novelty: This mAb specifically detects oligomers with no interference from peptides/proteins and targets the carbohydrate portions of tumor associated carbohydrate antigens (TACA) using an IgM antibody that is specific for surface carbohydrates specific for tumor cells. Includes methods of making and using monoclonal antibodies generated from immune responses to entirely carbohydrate immunogens, vaccine compositions, and pharmaceutical compositions.


Applications: With specific binding to the Tn cancer antigen, this technology will be a valuable tool for:

•       Immunotherapies for cancer

•       Excellent for diagnosis and prognosis of carcinomas


Value proposition:

•       Monoclonal IgM antibody is specific and selective for the Tn (D-GalNAc) cancer antigen.

•       As compared to a commercial mAb, our IgM can specifically recognize Tn without assistance from peptides or proteins or a combination of both.

•       Demonstrates exceptional binding to the glycoside portion of the Tn antigens in ELISA.

•       Since TACAs are present on the surface of most tumors, having a mAb that recognizes specific glycosides is an effective therapeutic strategy in light of the fact that most mAbs target proteins that are concealed beneath the glycocalyx.

•       The IgM mAb offers greater avidity because of multiple fragment antigen-binding sites (this is an absolute requirement since the target antigen is Tn (sugars)).

•       Technology is highly consistent and reproducible with no batch-to-batch variation.


Patent Information:
For Information, Contact:
Kwaku Opoku
Licensing Associate
The University of Toledo
Peter Andreana
Kevin Trabbic
Mengchao Shi
Jean Bourgault